Warther Private Wealth LLC Acquires Shares of 33,215 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Warther Private Wealth LLC purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 33,215 shares of the specialty pharmaceutical company's stock, valued at approximately $3,700,000. Jazz Pharmaceuticals makes up approximately 1.3% of Warther Private Wealth LLC's portfolio, making the stock its 22nd largest holding. Warther Private Wealth LLC owned approximately 0.05% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 116 shares during the period. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on JAZZ. Piper Sandler decreased their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. Wells Fargo & Company reduced their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 1st. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research note on Monday, August 19th. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $173.43.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company's stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ JAZZ traded up $1.50 during trading on Friday, hitting $109.55. The stock had a trading volume of 505,806 shares, compared to its average volume of 541,919. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.48. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The company has a market capitalization of $6.76 billion, a PE ratio of 18.82, a PEG ratio of 1.41 and a beta of 0.57. The firm has a fifty day moving average of $110.98 and a two-hundred day moving average of $109.61.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.06 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.